MedTrace Logo

A Clinical Study to Assess the Effect of Clopidogrel on the Pharmacokinetics of Selexipag and Its Active Metabolite in Healthy Male Subjects

NCT03496506 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2025-06-22

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effect of clopidogrel on the pharmacokinetics of selexipag and its active metabolite (ACT-333679) in healthy male adults (by determining the blood concentrations of selexipag and its metabolite). Also, the safety of selexipag when administered alone or with clopidogrel will be assessed.

Conditions

  • Healthy Subjects

Interventions

DRUG

Selexipag

Each film-coated tablet contains 200 microgram (mcg) of selexipag (oral use)

DRUG

Clopidogrel

Each film-coated tablet containing 75 mg of clopidogrel (oral use)

Sponsors & Collaborators

  • Actelion

    lead INDUSTRY

Principal Investigators

  • Shirin Bruderer · Actelion

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-03-05
Primary Completion
2018-05-10
Completion
2018-05-18

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03496506 on ClinicalTrials.gov